Jinyang Pharm's anti-SARS therapy is spotlighted in Southeast markets

Published: 2003-05-27 06:57:00

Updated: 2003-05-27 06:57:00

As the outbreak of severe acute respiratory syndrome is hitting the Southeast regions, Jinyang Pharm's combination therapy of ribavirin plus steroid preparations there has been popular in the treatment of SARS and hepatitis C.

According to Jinyang Pharm, the first shipment of ribavirin toward...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK